CIK 1622627
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 74.02% | 24 |
| Health Care Equipment & Supplies | 19.11% | 5 |
| Life Sciences Tools & Services | 5.48% | 1 |
| Unclassified | 1.39% | 2 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | DCTH | DELCATH SYSTEMS, INC. | Health Care | 12.55% |
| 2 | XERS | Xeris Biopharma Holdings, Inc. | Health Care | 7.68% |
| 3 | FENC | FENNEC PHARMACEUTICALS INC. | Health Care | 7.33% |
| 4 | SVRA | Savara Inc | Health Care | 7.17% |
| 5 | PCVX | Vaxcyte, Inc. | Health Care | 6.90% |
| 6 | EYPT | EyePoint, Inc. | Health Care | 5.48% |
| 7 | XFOR | X4 Pharmaceuticals, Inc | Health Care | 5.44% |
| 8 | VOR | Vor Biopharma Inc. | Health Care | 5.12% |
| 9 | MDWD | MediWound Ltd. | Health Care | 4.94% |
| 10 | VSTM | Verastem, Inc. | Health Care | 4.64% |
30/32 names classified · sector 98.6% of weight · industry 98.6% · mkt cap 93.7%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 98.6% of the book is sector-classified (unclassified names shown, never dropped).
Only 16% of book weight classified — the grid is NOT representative of the whole book.
Classified: 16.1% of book weight (2/32 names) · unclassified 83.9%: XERS, FENC, SVRA, PCVX, EYPT, XFOR, VOR, MDWD, VSTM, CLDX +20 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | DCTHDELCATH SYS INC | 3,300,389 | $31M | 12.5% | HOLD |
| 2 | XERSXERIS BIOPHARMA HOLDINGS INC | 3,231,700 | $19M | 7.7% | ADD 53% |
| 3 | FENCFENNEC PHARMACEUTICALS INC | 2,908,201 | $18M | 7.3% | ADD 11% |
| 4 | SVRASAVARA INC | 3,203,721 | $17M | 7.2% | TRIM −6% |
| 5 | PCVXVAXCYTE INC | 290,000 | $17M | 6.9% | NEW |
| 6 | EYPTEYEPOINT INC | 1,036,737 | $13M | 5.5% | ADD 50% |
| 7 | XFORX4 PHARMACEUTICALS INC | 3,214,766 | $13M | 5.4% | ADD 23% |
| 8 | VORVOR BIOPHARMA INC | 700,000 | $12M | 5.1% | NEW |
| 9 | MDWDMEDIWOUND LTD | 749,054 | $12M | 4.9% | HOLD |
| 10 | VSTMVERASTEM INC | 2,138,475 | $11M | 4.6% | ADD 20% |
| 11 | CLDXCELLDEX THERAPEUTICS INC NEW | 330,000 | $10M | 4.3% | NEW |
| 12 | BCRXBIOCRYST PHARMACEUTICALS INC | 923,057 | $9M | 3.6% | NEW |
| 13 | HELPCYBIN INC | 1,531,814 | $7M | 3.0% | TRIM −8% |
| 14 | CGONCG ONCOLOGY INC | 100,000 | $7M | 2.8% | TRIM −67% |
| 15 | NSPRINSPIREMD INC | 3,905,743 | $6M | 2.6% | HOLD |
| 16 | AVIRATEA PHARMACEUTICALS INC | 1,171,855 | $6M | 2.6% | NEW |
| 17 | PROFPROFOUND MED CORP | 828,118 | $5M | 2.2% | TRIM −23% |
| 18 | VRDNVIRIDIAN THERAPEUTICS INC | 250,401 | $5M | 2.0% | TRIM −44% |
| 19 | PYPDPOLYPID LTD | 597,926 | $3M | 1.1% | TRIM −14% |
| 20 | MYOMYOMO INC | 3,847,272 | $3M | 1.1% | HOLD |
| 21 | TLPHTALPHERA INC | 3,353,916 | $3M | 1.0% | TRIM −6% |
| 22 | OVIDOVID THERAPEUTICS INC | 1,107,994 | $2M | 1.0% | NEW |
| 23 | DFTXDEFINIUM THERAPEUTICS INC COM SHS | 125,000 | $2M | 1.0% | NEW |
| 24 | OKURONKURE THERAPEUTICS INC | 443,763 | $2M | 0.8% | TRIM −39% |
| 25 | LPCNLIPOCINE INC NEW | 221,616 | $2M | 0.7% | NEW |
| 26 | NRXSNEURAXIS INC | 286,138 | $2M | 0.7% | HOLD |
| 27 | AVTXAVALO THERAPEUTICS INC | 75,000 | $1M | 0.5% | NEW |
| 28 | ANNXANNEXON INC | 200,000 | $1M | 0.5% | NEW |
| 29 | AQSTAQUESTIVE THERAPEUTICS INC | 250,000 | $1M | 0.4% | NEW |
| 30 | BFRIBIOFRONTERA INC | 1,163,962 | $941,645 | 0.4% | ADD 2% |
| 31 | KURAKURA ONCOLOGY INC | 100,000 | $813,000 | 0.3% | HOLD |
| 32 | RGNTREGENTIS BIOMATERIALS LTD | 251,510 | $768,363 | 0.3% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| DCTHDELCATH SYS INC | 2.7M | 2.9M | 3.3M | 3.3M | 3.3M | 3.3M | $31M |
| XERSXERIS BIOPHARMA HOLDINGS INC | 3.1M | 2.5M | 2.2M | 1.8M | 2.1M | 3.2M | $19M |
| FENCFENNEC PHARMACEUTICALS INC | 1.3M | 1.8M | 2.0M | 2.1M | 2.6M | 2.9M | $18M |
| SVRASAVARA INC | 2.7M | 2.7M | 2.7M | 4.0M | 3.4M | 3.2M | $17M |
| PCVXVAXCYTE INC | — | — | — | — | — | 290K | $17M |
| EYPTEYEPOINT INC | — | — | — | 650K | 690K | 1.0M | $13M |
| XFORX4 PHARMACEUTICALS INC | — | — | — | 1.5M | 2.6M | 3.2M | $13M |
| VORVOR BIOPHARMA INC | — | — | — | — | — | 700K | $12M |
| MDWDMEDIWOUND LTD | 628K | 507K | 407K | 749K | 749K | 749K | $12M |
| VSTMVERASTEM INC | 900K | 2.6M | 2.0M | 1.9M | 1.8M | 2.1M | $11M |
| CLDXCELLDEX THERAPEUTICS INC NEW | — | — | — | — | — | 330K | $10M |
| BCRXBIOCRYST PHARMACEUTICALS INC | — | — | — | — | — | 923K | $9M |
| HELPCYBIN INC | 811K | 811K | 811K | 1.5M | 1.7M | 1.5M | $7M |
| CGONCG ONCOLOGY INC | — | — | 193K | 300K | 300K | 100K | $7M |
| NSPRINSPIREMD INC | 2.5M | 2.3M | 2.3M | 3.9M | 3.9M | 3.9M | $6M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
